The biology of aseptic osteolysis

Clinical Orthopaedics and Related Research

Volumn 460, Issue , 2007, Pages 240-252

  Holt, G ^a   Murnaghan, C ^a   Reilly, J ^b   Meek, R M D ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITONIN RECEPTOR; CATHEPSIN K; COLECALCIFEROL; COLONY STIMULATING FACTOR 1; DENOSUMAB; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 18; INTERLEUKIN 6; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE; VITRONECTIN RECEPTOR; CYTOKINE; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ASEPTIC OSTEOLYSIS; BONE ATROPHY; BONE REMODELING; CINAHL; COCHRANE LIBRARY; DRUG EFFICACY; EMBASE; FOREIGN BODY REACTION; GENE TARGETING; HUMAN; INFORMATION RETRIEVAL; MEDICAL LITERATURE; MEDLINE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTHESIS FAILURE; PROSTHESIS INFECTION; PROSTHESIS LOOSENING; REVIEW; SIGNAL TRANSDUCTION; STRESS STRAIN RELATIONSHIP; THERAPY EFFECT; TOTAL HIP PROSTHESIS; TREATMENT RESPONSE; HIP ARTHROPLASTY; HIP PROSTHESIS; IMMUNOLOGY; PATHOLOGY; PROSTHESIS;

ARTHROPLASTY, REPLACEMENT, HIP; CYTOKINES; HIP PROSTHESIS; HUMANS; OSTEOLYSIS; OSTEOPROTEGERIN; PROSTHESIS DESIGN; PROSTHESIS FAILURE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 34447339921     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/BLO.0b013e31804b4147     Document Type: Review

References (139)

1. Al-Saffar N, Khwaji HA, Kadoya Y, Revell PA. Assessment of the role of GM-CSF in the cellular transformation and the development of erosive lesions around orthopaedic implants. Am J Clin Pathol. 1996;105:628-633.
2. Al-Saffar N, Revell PA. Differential expression of transforming growth factor-a and macrophage colony stimulating factor/colony-stimulating factor-1R (c-fms) by multinucleated giant cells involved in pathological bone resorption at the site of orthopaedic implants. J Orthop Res. 2000;18:800-807.
3. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-179.
4. Baumann B, Rader CP, Seufert J, Noth U, Rolf O, Eulert J, Jakob F. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. Acta Orthop Scand. 2004;75:295-302.
5. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2005;20:2275-2282.
6. Benson MK, Goodwin PG, Brostoff J. Metal sensitivity in patients with joint replacement arthroplasties. BMJ. 1975;4:374-375.
7. Berry DJ, Harmsen WS, Cabanela ME, Morrey BF. Twenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements. J Bone Joint Surg Am. 2002;84:171-177.
8. Blaine TA, Pollice PF, Rosier RN, Reynolds PR, Puzas JE, O'Keefe RJ. Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents: the role of cAMP-mediated signaling mechanisms. J Bone Joint Surg Am. 1997;79:1519-1528.
9. Bragdon CR, Jasty M, Muratoglu OK, O'Connor DO, Harris WH. Third body wear of highly cross-linked polyethylene in a hip simulator. J Arthroplasty. 2003;18:553-561.
10. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268.
11. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999;145:527-538.
12. Callaghan JJ, Albright JC, Goetz DD, Olejniczak JP, Johnston RC. Charnley total hip arthroplasty with cement: minimum twenty-five-year follow-up. J Bone Joint Surg Am. 2000;82:487-497.
13. Campbell P, Ma S, Yeom B, McKellop H, Schmalzried TP, Amstutz HC. Isolation of predominantly submicron-sized UHMWPE wear particles from periprosthetic tissues. J Biomed Mater Res. 1995;29:127-131.
14. Chandler HP, Reineck FT, Wixson RL, McCarthy JC. Total hip replacement in patients younger than thirty years old: a five-year follow-up study. J Bone Joint Surg Am. 1981;63:1426-1434.
15. Chiba J, Rubash H, Kim KJ, Iwaki Y. The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clin Orthop Relat Res. 1994;300:304-312.
16. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Effect of antitumor necrosis factor-alpha gene therapy on wear debris-induced osteolysis. J Bone Joint Surg Am. 2001;83:1789-1797.
17. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Efficacy of etanercept for wear debris-induced osteolysis. J Bone Miner Res. 2001;16:338-347.
18. Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res. 2002;17:192-199.
19. Clohisy JC, Frazier E, Hirayama T, Abu-Amer Y. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. J Orthop Res. 2003;21:202-212.
20. Clohisy JC, Hirayama T, Frazier E, Han SK, Abu-Amer Y. NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis. J Orthop Res. 2004;22:13-20.
21. Clohisy JC, Teitelbaum S, Chen S, Erdmann JM, Abu-Amer Y. Tumor necrosis factor-alpha mediates polymethylmethacrylate particle-induced NF-kappaB activation in osteoclast precursor cells. J Orthop Res. 2002;20:174-181.
22. Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkB, RANK ligand and osteoprotegerin. Biomaterials. 2004;25:565-573.
23. Dlima DD, Hermida JC, Chen PC, Colwell CW Jr. Polyethylene cross-linking by two different methods reduces acetabular liner wear in a hip joint wear simulator. J Orthop Res. 2003;21:761-766.
24. Dobzyniak M, Fehring TK, Odum S. Early failure in total hip arthroplasty. Clin Orthop Relat Res. 2006;447:76-78.
25. Doorn PF, Campbell PA, Worrall J, Benya PD, McKellop HA, Amstutz HC. Metal wear particle characterization from metal on metal total hip replacements: transmission electron microscopy study of periprosthetic tissues and isolated particles. J Biomed Mater Res. 1998;42:103-111.
26. Dorr LD, Kane TJ III, Conaty JP. Long-term results of cemented total hip arthroplasty in patients 45 years old or younger: a 16-year follow-up study. J Arthroplasty. 1994;9:453-456.
27. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13:2412-2424.
28. Elves MW, Wilson JN, Scales JT, Kemp HB. Incidence of metal sensitivity in patients with total joint replacements. BMJ. 1975;4:376-378.
29. Endo MM, Barbour PS, Barton DC, Fisher J, Tipper JL, Ingham E, Stone MH. Comparative wear and wear debris under three different counterface conditions of crosslinked and non-crosslinked ultra high molecular weight polyethylene. Biomed Mater Eng. 2001;11:23-35.
30. Evans EM, Freeman MAR, Miller AJ, Vernon-Roberts B. Metal sensitivity as a cause of bone necrosis and loosening of the prosthesis in total joint replacement. J Bone Joint Surg Br. 1974;56:626-642.
31. Felix R, Hofstetter W, Cecchini MG. Recent developments in the understanding of the pathophysiology of osteopetrosis. Eur J Endocrinol. 1996;134:143-156.
32. Ferrier GM, McEnvoy A, Evans CE, Andrew JG. The effect of cyclic pressure on human monocyte-derived macrophages in vitro. J Bone Joint Surg Br. 2000;82:755-759.
33. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 1998;188:997-1001.
34. Galante JO, Lemons J, Spector M, Wilson PD, Wright TM. The biologic effects of implant materials. J Orthop Res. 1991;9:760-775.
35. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, Wong W, Kamen R, Tracey D, Allen H. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature. 1997;386:619-623.
36. Glant TT, Jacobs JJ. Response of three murine macrophage populations to particulate debris: bone resorption in organ cultures. J Orthop Res. 1994;12:720-731.
37. Glant TT, Jacobs JJ, Molnar G, Shanbhag AS, Valyon M, Galante JO. Bone resorption activity of particulate-stimulated macrophages. J Bone Miner Res. 1993;8:1071-1079.
38. Goater JJ, O'Keefe RJ, Rosier RN, Puzas JE, Schwarz EM. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res. 2002;20:169-173.
39. Goldring SR, Schiller AL, Roelke M, Rourke CM, O'Neil DA, Harris WH. The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Joint Surg Am. 1983;65:575-584.
40. Goodman SB, Chin RC, Chiou SS, Schurman DJ, Woolson ST, Masada MP. A clinical-pathologic-biochemical study of the membrane surrounding loosened and non-loosened total hip arthroplasties. Clin Orthop Relat Res. 1989;244:182-187.
41. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest. 1999;104:1393-1401.
42. Greenfield EM, Bi Y, Ragab AA, Goldberg VM, Van De Motter RR. The role of osteoclast differentiation in aseptic loosening. J Orthop Res. 2002;20:1-8.
43. Hallab NJ, Anderson S, Caicedo M, Skipor A, Campbell P, Jacobs JJ. Immune responses correlate with serum-metal in metal-on-metal hip arthroplasty. J Arthroplasty. 2004;19:88-93.
44. Hallab NJ, Anderson S, Stafford T, Glant T, Jacobs JJ. Lymphocyte responses in patients with total hip arthroplasty. J Orthop Res. 2005;23:384-391.
45. Hallab N, Merritt K, Jacobs JJ. Metal sensitivity in patients with orthopaedic implants. J Bone Joint Surg Am. 2001;83:428-436.
46. Hamadouche M, Boutin P, Dassange J, Bolander ME, Sedel L. Alumina-on-alumina total hip arthroplasty: a minimum 18.5-year follow-up study. J Bone Joint Surg Am. 2002;84:69-77.
47. Hart AJ, Hester T, Sinclair K, Powell JJ, Goodship AE, Pele L, Fersht NL, Skinner J. The association between metal ions from hip resurfacing and reduced T-cell counts. J Bone Joint Surg Br. 2006;88:449-454.
48. Hatton A, Nevelos JE, Matthews JB, Fisher J, Ingham E. Effects of clinically relevant alumina ceramic wear particles on TNF-a production by human peripheral blood mononuclear cells. Biomaterials. 2003;24:1193-1204.
49. Haynes DR, Rogers SD, Hay S, Pearcy MJ, Howie DW. The differences in toxicity and release of bone-resorbing mediators induced by titanium and cobalt-chromium-alloy wear particles. J Bone Joint Surg Am. 1993;75:825-834.
50. Heisel C, Silva M, Schmalzried TP. Bearing surface options for total hip replacements in young patients. Instr Course Lect. 2004;53:49-65.
51. Herman JH, Sowder WG, Anderson D, Appel AM, Hopson CN. Polymethylmethacrylate induced release of bone-resorbing factors. J Bone Joint Surg Am. 1989;71:1530-1541.
52. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000;15:2-12.
53. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999;140:4367-4370.
54. Hopper RH Jr, Young AM, Orishimo KF, McAuley JP. Correlation between early and late wear rates in total hip arthroplasty with application to the performance of marathon cross-linked polyethylene liners. J Arthroplasty. 2003;18:60-67.
55. Horowitz SM, Algan SA, Purdon MA. Pharmacologic inhibition of particulate-induced bone resorption. J Biomed Mater Res. 1996;31:91-96.
56. Howie DW, Haynes DR, Rogers SD, McGee MA, Pearcy MJ. The response to particulate debris. Orthop Clin North Am. 1993;24:571-581.
57. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 1999;96:3540-3545.
58. Im GI, Han JD. Suppressive effects of interleukin-4 and interleukin-10 on the production of proinflammatory cytokines by titanium-alloy particles. J Biomed Mater Res. 2001;58:531-536.
59. Ingram JH, Stone MH, Fisher J, Ingham E. The influence of molecular weight, crosslinking and counterface roughness on TNF-alpha production by macrophages in response to ultra high molecular weight polyethylene particles. Biomaterials. 2004;25:3511-3522.
60. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med. 1997;3:1285-1289.
61. Jacobs JJ, Hallab NJ. Loosening and osteolysis associated with metal-on-metal bearings: a local effect of metal hypersensitivity? J Bone Joint Surg Am. 2006;88:1171-1172.
62. Jacobs JJ, Hallab NJ, Skipor AK, Urban RM. Metal degradation products: a cause for concern in metal-metal bearings? Clin Orthop Relat Res. 2003;417:139-147.
63. Jiranek WA, Machado M, Jasty M. Production of cytokines around loosened cemented acetabular components: analysis with immunohistochemical techniques and in situ hybridization. J Bone Joint Surg Am. 1993;75:863-879.
64. Joshi AB, Porter ML, Trail IA, Hunt LP, Murphy JC, Hardinge K. Long-term results of Charnley low-friction arthroplasty in young patients. J Bone Joint Surg Br. 1993;75:616-623.
65. Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone. 1995;17(suppl):S101-S105.
66. Kavanagh BF, Wallrichs S, Dewitz M, Berry D, Currier B, Ilstrup D, Coventry MB. Charnley low-friction arthroplasty of the hip: twenty-year results with cement. J Arthroplasty. 1994;9:229-234.
67. Kim KJ, Kotake S, Udagawa N, Ida H, Ishii M, Takei I, Kubo T, Takagi M. Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. J Biomed Mater Res. 2001;58:393-400.
68. Kim KJ, Rubash H, Wilson SC, D'Antonio JA, McClain EJ. A histologic and biochemical comparison of the interface tissues in cementless and cemented hip prostheses. Clin Orthop Relat Res. 1993;287:142-152.
69. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323.
70. Lacey DL, Timms E, Tan HL, Keeley MJ, Dunstan CR, Burgess T. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.
71. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA. 2000;97:1566-1571.
72. Liew FY, Wei XQ, McInnes IB. Role of interleukin 18 in rheumatoid arthritis. Ann Rheum Dis. 2003;62(suppl 2):ii48-ii50.
73. Lohmann CH, Schwartz Z, Koster G, Jahn U, Buchhorn GH, MacDougall MJ, Casasola D, Liu Y, Sylvia VL, Dean DD, Boyan BD. Phagocytosis of wear debris by osteoblasts affects differentiation and local factor production in a manner dependent on particle composition. Biomaterials. 2000;21:551-561.
74. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP. Evidence for a role of a tumor necrosis factor alpha (TNF-alpha)-converting enzyme like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem. 1999;274:13613-13618.
75. Malchau H, Herberts P, Eisler T, Garellick G, Soderman P. The Swedish Total Hip Replacement Register. J Bone Joint Surg Am. 2002;84(suppl 2):2-20.
76. Maloney WJ, Smith RL. Periprosthetic osteolysis in total hip arthroplasty: the role of particulate wear debris. Instr Course Lect. 1996;45:171-182.
77. Maloney WJ, Smith RL, Hvene D, Schmalzried TP, Rubash H. Isolation and characterization of wear debris generated in patients who have had failure of a hip arthroplasty without cement. J Bone Joint Surg Am. 1994;77:1301-1310.
78. Mandelin J, Li TF, Liljeström M, Kroon ME, Hanemaaijer R, Santavirta S, Konttinen YT. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. J Bone Joint Surg Br. 2003;85:1196-1201.
79. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332:305-311.
80. Margevicius KT, Bauer TW, McMahon JT, Brown SA, Merritt K. Isolation and characterization of debris from around total joint prostheses. J Bone Joint Surg Am. 1994;76:1664-1675.
81. Martin SF. T lymphocyte-mediated immune responses to chemical haptens and metal ions: implications for allergic and autoimmune disease. Int Arch Allergy Immunol. 2004;134:186-198.
82. Matthews JB, Mitchell W, Stone MH, Fisher J, Ingham E. A novel three-dimensional tissue equivalent model to study the combined effects of cyclic mechanical strain and wear particles on the osteolytic potential of primary human macrophages in vitro. Proc Inst Mech Eng [H]. 2001;215:479-486.
83. Matthews JB, Mitchell W, Stone MH, Fisher J, Ingham E. Synergistic effect of cyclic strain and particulate polyethylene on the production of TNF by activated primary human mononuclear phagocytes. Trans Orthop Res Soc [serial online]. 2001;26:Paper No. 0218. Available at: http://www.ors.org/web/ Transactions/47/0218.PDF.
84. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821-831.
85. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum S. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol. 1999;154:203-210.
86. Millet PJ, Allen MJ, Bostrom MP. Effects of alendronate on particle-induced osteolysis in a rat model. J Bone Joint Surg Am. 2002;84:236-249.
87. Mizuno A, Murakami A, Nakagawa N, Yasuda H, Tsuda E, Morinaga T, Higashio K. Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. Gene. 1998;215:339-343.
88. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell. 1993;75:274-282.
89. Mostov K, Werb Z. Journey across the osteoclast. Science. 1997;276:219-220.
90. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med. 1998;187:2103-2108.
91. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 1998;253:395-400.
92. Nakashima Y, Sun DH, Trindade MC, Maloney WJ, Goodman SB, Schurman DJ, Smith RL. Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J Bone Joint Surg Am. 1999;81:603-615.
93. Neale SD, Athanasou NA. Cytokine receptor profile of arthroplasty macrophages foreign body giant cells and mature osteoclasts. Acta Orthop Scand. 1999;70:452-458.
94. Nevelos JE, Ingham E, Doyle C, Nevelos AB, Fisher J. Wear of HIPed and non-HIPed alumina-alumina hip joints under standard and severe simulator testing conditions. Biomaterials. 2001;22:2191-2197.
95. NIH Consensus Development Panel on Total Hip Replacement. Total hip replacement. NIH Consensus Conference. JAMA. 1995;273:1950-1956.
96. Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K. Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol. 1998;10:259-264.
97. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature. 1995;378:88-91.
98. Olee T, Hashimoto S, Quach J, Lotz M. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol. 1999;162:1096-1100.
99. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mince: a critical requirement in TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med. 1996;184:1397-1411.
100. Pizzoferrato A, Ciapetti G, Stea S, Toni A. Cellular events in the mechanisms of prosthesis loosening. Clin Mater. 1991;7:51-81.
101. Popoff SN, Schneider GB. Animal models of osteopetrosis: the impact of recent molecular developments on novel strategies for therapeutic intervention. Mol Med Today. 1996;2:349-358.
102. Ragab AA, Van De Motter R, Lavish SA, Goldberg VM, Ninomiya JT, Carlin CR, Greenfield EM. Measurement and removal of adherent endotoxin from titanium particles and implant surfaces. J Orthop Res. 1999;17:803-809.
103. Reddi AH. Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state. Cell. 1997;89:159-161.
104. Ries MD, Scott ML, Jani S. Relationship between gravimetric wear and particle generation in hip simulators: conventional compared with cross-linked polyethylene. J Bone Joint Surg Am. 2001;83:116-122.
105. Roodman GD. Advances in bone biology: the osteoclast. Endocr Rev. 1996;17:308-332.
106. Rosen CJ, Kessenich CR. The pathophysiology and treatment of postmenopausal osteoporosis: an evidence-based approach to estrogen replacement therapy. Endocrinol Metab Clin North Am. 1997;26:295-311.
107. Sabokbar A, Rushton N. Role of inflammatory mediators and adhesion molecules in the pathogenesis of aseptic loosening in total hip arthroplasties. J Arthroplasty. 1995;10:810-815.
108. Saika M, Inoue D, Kido S, Matsumoto T. 17 beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor alpha. Endocrinology. 2001;142:2205-2222.
109. Santavirta S, Holkka V, Eskola A, Kontinen YT, Paavilainen T, Tallroth K. Aggressive granulomatous lesions in cementless total hip arthroplasty. J Bone Joint Surg Br. 1990;72:980-984.
110. Santavirta S, Konttinen Y, Bergroth V, Gronblad M. Lack of immune response to methyl methacrylate in lymphocyte cultures. Acta Orthop Scand. 1991;62:29-32.
111. Sarmiento A, Ebramzadeh E, Gogan WJ, McKellop HA. Total hip arthroplasty with cement: a long-term radiographic analysis in patients who are older than fifty and younger than fifty years. J Bone Joint Surg Am. 1990;72:1470-1476.
112. Schmidt C, Steinbach G, Decking R, Claes LE, Ignatius AA. IL-6 and PGE2 release by human osteoblasts on implant materials. Biomaterials. 2003;24:4191-4196.
113. Schulte KR, Callaghan JJ, Kelley SS, Johnston RC. The outcome of Charnley total hip arthroplasty with cement after a minimum twenty-year follow-up: the results of one surgeon. J Bone Joint Surg Am. 1993;75:961-975.
114. Schwarz E, Bukata S, Benz E, Rosier RN, Puzas JE, O'Keefe RJ. NF-κB and TNF-alpha are stimulated by titanium particles and are essential for in vivo bone resorption. Trans Orthop Res Soc [serial online]. 1999;24:Paper No. 305. Available at: http://www.ors.org/web/Transactions/45/ 0305.PDF.
115. Schwarz EM, Campbell D, Totterman S, Boyd A, O'Keefe RJ, Looney RJ. Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo. J Orthop Res. 2003;21:1049-1055.
116. Schwarz EM, Lu AP, Goater JJ, Benz EB, Kollias G, Rosier RN, Puzas JE, O'Keefe RJ. Tumor necrosis factor-alpha/nuclear transcription factor-kappaB signaling in periprosthetic osteolysis. J Orthop Res. 2000;18:472-480.
117. Schwarz EM, O'Keefe RJ. Breakthrough in bone: the molecular mechanism of osteoclast/osteoblast coupling revealed. Curr Opin Orthop. 2000;11:329-335.
118. Seitz M, Hunstein W. Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus. Ann Rheum Dis. 1985;44:438-445.
119. Shanbhag AS, Hasselman CT, Rubash HE. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop Relat Res. 1997;344:33-43.
120. Shanbhag AS, Jacobs JJ, Glant T, Gilbert JL, Black J, Galante JO. Composition and morphology of wear debris in failed uncemented total hip replacement. J Bone Joint Surg Br. 1994;76:60-67.
121. Sharp DJ, Porter KM. The Charnley total hip arthroplasty in patients under age 40. Clin Orthop Relat Res. 1985;201:51-56.
122. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sanders S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
123. Stoll S, Jonuleit H, Schmitt E, Muller G, Yamauchi H, Kurimoto M, Knop J, Enk AH. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol. 1998;28:3231-3239.
124. Stoll S, Muller G, Kurimoto M, Saloga J, Tanimoto T, Yamauchi H, Okamura H, Knop J, Enk AH. Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol. 1997;159:298-301.
125. Takei I, Takagi M, Ida H, Ogino T, Santavirta S, Konttinen YT. High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints. J Rheumatol. 2000;27:894-899.
126. Teitelbaum SI. The osteoclast and osteoporosis. Mt Sinai J Med. 1996;63:399-402.
127. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504-1508.
128. Thadani PJ, Waxman B, Sladek E, Barmada R, Gonzalez MH. Inhibition of particulate debris-induced osteolysis by alendronate in a rat model. Orthopedics. 2002;25:59-63.
129. Theill LE, Boyle WK, Penninger JM. RANKL and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002;20:795-823.
130. Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ, Gillespie MT. Interleukin-18 (interferon-gamma- inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med. 1997;185:1005-1012.
131. Vermes C, Chandrasekaran R, Jacobs JJ, Galante JO, Roebuck KA, Glant TT. The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. J Bone Joint Surg Am. 2001;832:201-211.
132. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005;115:282-290.
133. Xu D, Trajkovic V, Hunter D, Leung BP, Schulz K, Gracie JA, McInnes IB, Liew FY. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol. 2000;30:3147-3156.
134. Xu JW, Konttinen YT, Lassus J, Natah S, Ceponis A, Solovieva S, Aspenberg P, Santavirta S. Tumor necrosis factor-alpha (TNF-a) in loosening of total hip replacement (THR). Clin Exp Rheumatol. 1996;14:643-648.
135. Xu JW, Li TF, Partsch G, Ceponis A, Santavirta S, Kontinnen YT. Interleukin-11 (IL-11) in aseptic loosening of total hip replacement (THR). Scand J Rheumatol. 1998;27:363-367.
136. Yamashita K, Iwasaki T, Tsujimura T, Sugihara A, Yamada N, Ueda H, Okamura H, Futani H, Maruo S, Terada N. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow. Oncol Rep. 2002;9:1237-1244.
137. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki SI. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998;95:3597-3602.
138. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139:1329-1337.
139. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 2004;50:277-290.